MYC and B-cell non-Hodgkin lymphoma: CBL0137 has been reported to block the cell cycle of aggressive B-cell non-Hodgkin lymphoma (B-NHL) cells at the S phase via the c-MYC/p53/p21 pathway, thereby inhibiting proliferation [38, 39].